RxDoctor Payments Data

Katherine Zwiebel

Nurse Practitioner · Saint Marys, OHNPI 1689102881

Payments from drug & device makers

$7,797in general payments, 2019–2025

Across 581 payments — averaging $13.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$530
  • AstraZeneca$423
  • Amneal Pharmaceuticals LLC$369
  • UCB, Inc.$359
  • SK Life Science, Inc.$357
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$7,779100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,797 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$112,713
Medicare patients
419
Services billed
7,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant98$136,145
NuplazidPimavanserin Tartrate19$131,820
BriviactBrivaracetam70$124,561
Nurtec OdtRimegepant Sulfate81$113,539
IngrezzaValbenazine Tosylate14$92,411
UbrelvyUbrogepant59$85,069
AptiomEslicarbazepine Acetate17$67,379
Aimovig AutoinjectorErenumab-Aooe40$45,096
GocovriAmantadine Hcl12$41,106
NourianzIstradefylline14$25,140
NamzaricMemantine Hcl/Donepezil Hcl29$24,050
Emgality PenGalcanezumab-Gnlm26$23,185
VimpatLacosamide18$20,715
Ajovy AutoinjectorFremanezumab-Vfrm14$13,840
Carbidopa-LevodopaCarbidopa/Levodopa246$8,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Namzaric$2,236$245,263186 claims
UCB, Inc.Briviact, Vimpat$359$145,27688 claims
Acadia Pharmaceuticals IncNuplazid$92$131,82019 claims
PfizerNurtec Odt$307$113,53981 claims
Neurocrine Biosciences, Inc.Ingrezza$530$92,41114 claims
Sunovion Pharmaceuticals Inc.Aptiom$98$67,37917 claims
MDD US Operations, LLCGocovri$17$41,10612 claims
Kyowa Kirin, Inc.Nourianz$104$25,14014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Saint Marys

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →